FDAnews
www.fdanews.com/articles/108581-alcon-ends-macular-degeneration-drug-program

Alcon Ends Macular Degeneration Drug Program

July 15, 2008

Alcon has terminated development of anecortave acetate as a treatment to lower the risk of age-related macular degeneration.

An analysis of two studies performed with 2,546 patients over 24 months showed that anecortave acetate had no effect on the study’s primary or secondary endpoints, the company said.

Alcon also ended two smaller, identically designed studies being conducted in Asia. The candidate also is being studied as a treatment for reducing intraocular pressure in patients with open-angle glaucoma, Alcon said.